far apart will the measurements be? With patients in MIYABI HD-M, will there be a period of time after switching from their pre-study ESA to darbepoetin? There may be a period of instability after switching and it may take time to fine tune the darbepoetin dose. A rationale for doing this, or not doing this, should be provided. Reference is made to a pharmacokinetic study is made in the middle of p8. Will this be for all patients or an optional substudy? How many samples are required to calculate AUC? Will this enrol patients from all three studies? What is the specific aim of doing this and what is the main outcome of interest? Where two primary outcomes are listed (MIYABI HD-C), how will the rate of rise be assessed statistically? As in the non-dialysis studies, requiring the upper and lower bounds of each individual patients mean Hb from 4 measures to be within range may prove too stringent. Why has this approach been taken? Why do previous ESA dose and previous thromboembolic events need to be included in the ANCOVA model for change in Hb? As stated, the sample sizes for MIYABI HD-C and MIYABI PD are determined on "feasibility" and the purpose of these trials, and whether to conduct them at all, should be reconsidered. The sample size for MIABI HD-M gives two levels of power. The non-inferiority to molidustat assumptions are given. However, the ">=98% power" to establish that mean Hb levels are within target range is not explained. This should be expanded upon. Is this based on mean levels or on the proportion of patients within the target? What assumptions were used for this power calculation? Discussion: Om p10, line 22 -"It is anticipated that the three phase three trials described here" -are MIYABI HD-C and MIYABI PD really phase 3 trials (and also p11, line 22)? It is stated that Ethics approval has been obtained. The name of the Ethics Committee and the application number should be provided. A timeline for the actual study would be helpful. Has the study commenced recruiting? When is recruiting anticipated to finish? The SPIRIT checklist is not specifically referred to.
REVIEWER
Bruce Spinowitz New York Presbyterian Queens Weill Cornell School of Medicine USA REVIEW RETURNED 20-Nov-2018
GENERAL COMMENTS
1-The trials are not adequately powered to assess safety issues related to major atherosclerotic CV events-which is a significant issue for ESA use in the esrd population. 2-What is the frequency of VEGF level testing 3-Based on cited reference 22, any increase in EPO level , cannot be presumed to be of renal origin as stated in discussion(page 11) 4-A brief description of supplemental iron use should be stated , not simply reference on page 7(ref # 31)
REVIEWER

Titi Chen University of Sydney Australia
REVIEW RETURNED
07-Jan-2019
GENERAL COMMENTS
The manuscript entitled "Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase 3 studies" reports the methodologies of three Japanese trials investigating the efficacy of HIF-PHI Molidustat in dialysis patients.
Molidustat is one of four HIF-PHI, which have completed phase 2 trial and are currently undergoing phase 3 clinical trials. The current manuscript consists of 3 trials, with the first being a noninferiority RCT (MIYABI HD-M) comparing Molidustat with Darbepoetin alfa. Compared with a previous open-label phase 2b trial, (DIALOGUE 4), the current study has a larger sample size and longer follow up period. The other two trials in the manuscript are single armed with relatively small sample size. These two trials, for the first time, investigated Molidustat in PD (MIYABI PD) patients and HD (MIYABI HD-C) patients not on ESA.
The studies are well designed. For phase 3 studies, one of the limitations of the trials was the relatively small sample size of the two single armed trials and the single armed design, which are due to feasibility and limited available patients.
Could the authors please kindly clarify the following : 1. For MIYABI HD-M, please detail the type of randomization and method used to randomize sample. 2. For MIYABI HD-M, please clarify who was blinded and how? 3. Please specify the role of study funder (Bayer) plays in the study design and data collection, analysis and interpretation. 4. Page 3 strengths and limitations of the studies -only strengths are discussed; limitations are not discussed.
VERSION 1 -AUTHOR RESPONSE
Response to reviewer comments Reviewer comment Response Revision Reviewer #1 This protocol manuscript applies to three studies so again, the reader needs to be clear what applies to all studies and what applies to the individual studies.
Several sentences and paragraphs have been revised as suggested.
'Methods and planned analysis' section
The "MIYABI" acronym is slightly misleading in that there is no assessment of symptoms in any of these studies (or the MIYABI ND ones).
Thank you for the comment. Upon reflection, the MIYABI acronym might be slightly misleading but the acronym has been described in the protocol which has been approved by the Japanese Pharmaceuticals and Medical Devices Agency.
No change
The objectives are stated generally on pp 5 (Introduction) for the suite of "MIYABI" trials. Also in the Introduction -the risks of ESAs are stated quite strongly in the second paragraph. Pure red cell aplasia is now exceedingly rare and the tumour progression is a potential risk that needs to be weighed against the benefits.
We agree that pure red cell aplasia (PRCA) is rare and have revised the sentence accordingly. We also deleted the text about tumour progression and made is clearer that thrombosis was in patients with cancer.
Line 80-83.
In the 3rd paragraph of the Introduction (line 46, p4), the "undesirable conditions" should be expanded upon.
We agree and have revised the sentence.
Lines 95 and 96
In referring to the phase 2 studies on p5, this should be referred to as "unpublished data" until the manuscript under consideration has been accepted.
We have included the recently published DIALOGUE studies paper (Macdougall et al, 2019 ) and refer to the DIALOGUE extension studies paper as "unpublished data".
Lines 114 and 115
The abbreviation "PD" is used for pharmacodynamics on p5 and for peritoneal dialysis in the Abstract, on p6 and possibly elsewheredifferent (or no) abbreviations should be used for these terms.
We agree. We now use the word "pharmacodynamics" instead of "PD".
Lines 119, 121 and 133 We appreciate the reviewer's concerns on this point. We understand the concern about the design of MIYABI HD-C and MIYABI PD and sample sizes, therefore we have highlighted these limitations further in the paper.
Line 311-316
The Screening period is not adequately described. How often will patients be seen during the screening period? Is eligibility based
We have now included a description of the screening periods in the text.
Line 136-141 on two measurements of Hb within the stated ranges? If so, how far apart will the measurements be? With patients in MIYABI HD-M, will there be a period of time after switching from their pre-study ESA to darbepoetin? There may be a period of instability after switching and it may take time to fine tune the darbepoetin dose. A rationale for doing this, or not doing this, should be provided.
The time period after switching from the pre-study ESAs takes into account the half-life of the ESA. Further details relating to this are specified in table 1.
"Treated with the same ESA for ≥8 weeks before randomisation (weekly or biweekly dose of darbepoetin alfa, monthly or biweekly dose of epoetin beta pegol, OR weekly, biweekly, twice or three times per week dose of epoetin alfa/beta, and having had no more than one dose change during the 8 weeks before randomisation)."
We have also included a description the time period for patients washed out from ESAs in a footnote under table1. "*For patients washed out from ESAs, the mean Hb level before dialysis (at least two measurements taken ≥2 days apart, assessed by the central laboratory) must have decreased by ≥0.5 g/dL after the last ESA administration, AND the interval from the last ESA administration to study drug assignment should be >1 week for epoetin alfa, >2 weeks for darbepoetin alfa or >4 weeks for epoetin beta pegol." Table 1 Reference is made to a pharmacokinetic study is made in the middle of p8. Will this be for all patients or an optional substudy? How many samples are required to calculate AUC? Will this enrol patients from all three studies? What is the specific aim of doing this and what is the main outcome of interest?
In the following sentence, which includes the aim of the PK work, we have made some revisions to clarify that this will be done as part of each study and that all patients will be involved: "In each study, to investigate systemic exposure to molidustat and the relationship between molidustat exposure and response, sparse sampling from all patients will be conducted for pharmacokinetics and pharmacodynamics".
With regard to the number of samples required to access pharmacokinetics, it's stated in the paper that "If possible, molidustat exposure parameters (eg, Cmax, AUC) and the relationship between molidustat exposure and treatment effects will be evaluated".
Line 224-226
The intention is to investigate the impact of intrinsic and extrinsic covariates on molidustat exposure. The magnitude of effect of selected covariates will be reported, if any.
Where two primary outcomes are listed (MIYABI HD-C), how will the rate of rise be assessed statistically?
Thank you for the comment. We have described in the following sentence: "In MIYABI HD-C, the primary efficacy variables (rate of rise in Hb and responder rate) and their two-sided 95% confidence intervals (CI) will be estimated using one-sample t-statistics and the Clopper-Pearson method, respectively".
No change (relevant lines are [240] [241] [242] As in the non-dialysis studies, requiring the upper and lower bounds of each individual patients mean Hb from 4 measures to be within range may prove too stringent. Why has this approach been taken?
The analysis for primary efficacy in MIYABI HD-M is that the mean of the mean Hb levels per patient is within target range, not all of 4 measurements of each patient Hb.
No change
Why do previous ESA dose and previous thromboembolic events need to be included in the ANCOVA model for change in Hb?
The ANCOVA model requires inclusion of thromboembolic events and previous ESA dose because the randomization will be stratified by previous ESA dose and previous thromboembolic events.
As stated, the sample sizes for MIYABI HD-C and MIYABI PD are determined on "feasibility" and the purpose of these trials, and whether to conduct them at all, should be reconsidered.
We appreciate the reviewer's concerns on this point. As we mentioned above, we understand the concern about the design of MIYABI HD-C and MIYABI PD and sample sizes, therefore we have highlighted these limitations further in the paper.
Line 311-316
The sample size for MIABI HD-M gives two levels of power. The noninferiority to molidustat assumptions are given. However, the ">=98% power" to establish that mean Hb levels are within target range is not explained. This should be expanded upon. Is this based on mean levels or on the proportion of patients within the target? What assumptions were used for this power calculation?
We have revised the sample size paragraph, which now includes the following explanation: "If 150 patients are randomised to the molidustat group, the power to establish that mean Hb levels are within target levels during the evaluation period is ≥98%, assuming a standard deviation of 1.3-1.5g/dL from the previous phase 2b studies".
Line 267-278
Om p10, line 22 -"It is anticipated that the three phase three trials described here" -are MIYABI HD-C and MIYABI PD really phase 3 trials (and also p11, line 22)?
We appreciate the reviewer's concerns on this point. As we mentioned above, we understand the concern about the design of MIYABI HD-C and MIYABI PD and sample sizes, therefore we We have included in the text that "The three trials commenced in the first half of 2018 and have finished recruiting".
Line 134-135
The SPIRIT checklist is not specifically referred to.
The protocols for all three studies were written in accordance with SPIRIT guidelines, with the exception of item number 15 (strategies for achieving adequate participant enrolment to reach target sample size) and 31b (authorship eligibility guidelines and any intended use of professional writers).
No change
Reviewer #2 1-The trials are not adequately powered to assess safety issues related to major atherosclerotic CV events which is a significant issue for ESA use in the esrd population.
We agree with the reviewer and have added text accordingly in the Discussion. We agree with the reviewer and have updated the manuscript accordingly. The following sentence has been added: "Iron supplementation will be administered to reach with a target serum ferritin level of at least 100 ng/mL or transferrin saturation of at least 20%".
Line 207-209
Reviewer #3 1. For MIYABI HD-M, please detail the type of randomization and method used to randomize sample.
The following sentence has been added: "Allocation to treatment arms will be achieved using an interactive voice/web response system (IxRS) at the first (baseline) visit".
Line 163-164 2. For MIYABI HD-M, please clarify who was blinded and how?
We have revised and added to the following text: "All investigators and patients in MIYABI HD-M will be blinded to treatment allocation. In cases of emergency, such as occurrence of a suspected, unexpected, serious AE, when the investigator needs to know which drug has been allocated, unblinding will occur by entering the emergency key code for the relevant patient into the IxRS". Why is EQ-5D-SL only noted in supplement? Mention it's use in Methods.
VERSION 2 -AUTHOR RESPONSE
Reviewer #1 comments Overall, the manuscript has been improved and most of the changes made appear appropriate. My residual concerns are listed below: An acronym indicating that the study is about symptoms when the "sYmptoms of renal Anaemia:" are not assessed at all still sits very uncomfortably with me, regardless of whether the protocol was approved by another agency. The main outcomes are related to haemoglobin levels. I find this problematic as the acronym is referred to throughout the protocol.
Thank you for your feedback. We understand your concern that the MIYABI acronym expansion is potentially misleading and therefore have changed it to the following: "MolIdustat once dailY improves renal Anemia By Inducing EPO".
Line 25-26
Line 119-120
The SPIRIT Guideline is listed but not as a checklist showing how and where each point is covered in the protocol.
The completed SPIRIT checklist is included below. 
